Looking for Lilly’s LY4086940? Its two registered trials, NCT06945419 and NCT07890376, are listed below. For what they test and what has not been disclosed, see the LY4086940 profile or our LY4086940 write-up.
2 registered trials, newest registry update first. Showing only trials linked to Trevogrumab.
| Trial | Compound | Phase | Status | Sponsor | Enrolled | Primary completion | Registry updated |
|---|---|---|---|---|---|---|---|
| A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss, Fat Loss, and Lean Mass Preservation NCT06299098 | Trevogrumab | Phase 2 | Active not recruiting | Regeneron Pharmaceuticals | 1,005 | Jun 16, 2026 | Sep 1, 2026 |
| Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia NCT01963598 | Trevogrumab | Phase 2 | Completed | Regeneron Pharmaceuticals | 253 | Jan 2015 | Mar 28, 2016 |
Data: ClinicalTrials.gov, U.S. National Library of Medicine. Registered trials only. This table does not report results or recommend anything.
